Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

A higher proportion of adolescents who tested positive for COVID-19 reported ongoing symptoms compared with those who tested negative or never tested.

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.

Expert consensus outlines diagnostic and therapeutic strategies for managing SARS-CoV-2 infection in solid organ transplant ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

The updated COVID-19 vaccines targeting the LP.8.1 variant have been approved by the FDA. But they may be a lot harder to get ...

Neurologic manifestations are common in children hospitalized with SARS-CoV-2 or multisystem inflammatory syndrome (MIS-C), ...

Immune profiles after COVID-19 vaccination predict booster need, with rapid-decliners at higher risk of breakthrough ...

From L-R, Garcia, Wahl and Battaglia Approximately 15 million to 20 million Americans who have acquired COVID-19 experience ...

The paper aims to increase awareness of cardiac long COVID and make management quicker, more accurate, and safer.

Moderna said on Tuesday its updated COVID-19 vaccine elicited a strong immune response in all adults age 65 and older, as ...